2 / 25
Evaluation of the Sensitivity of KRAS Mutation Detection
of the Idylla Platform in Comparison to
the OncoBEAM RAS CRC Assay
Ana Vivancos
1
, Enrique Aranda
2
, Manuel Benavides
3
, Elena Elez
4
,
M. Auxiliadora Gómez-España
2
, Marta Toledano
5
,
Martina Alvarez
6
, M. Rosario Chica Parrado
6
,
Vanesa García-Barberán
7
, and Eduardo Diaz-Rubio
7
1
Cancer Genomics Group, Vall d’Hebron Institute of Oncology, Barcelona;
2
Department of Medical Oncology, Reina Sofía University Hospital, CIBERONC, Córdoba;
3
Department of Medical Oncology, Hospital Universitario Regional y Virgen de la Victoria Málaga;
4
Department of Medical Oncology Vall d’Hebron Institute of Oncology Barcelona;
5
IMIBIC Instituto Maimonides Investigación Biomédica de Córdoba;
6
Laboratorio de Biología Molecular del Cáncer-Centro de Investigaciones Médico Sanitarias Málaga;
7
Laboratorio de Investigación Traslacional, IdISSC, Hospital Clínico San Carlos, CIBERONC, Madrid
Ana Vivancos et al. - Poster 592
ASCO GI Congress
January 20, 2018 - San Francisco, California
Presenters: Drs. Enrique Aranda and Manuel Benavides